Clinical Trial Update: An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

View source ↗

Summary

Observational study of patients treated with trastuzumab deruxtecan (Enhertu) for HER2-positive and HER2-low unresectable/metastatic breast cancer; the trial st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Low Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Status: TERMINATED